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Abstract 
Skin disorders, usually neglected and frequently underdiagnosed among diabetic patients, are common complica-
tions and encounter a broad spectrum of disorders in both type 1 and type 2 diabetes mellitus (DM)—e.g. cutaneous 
infection, dry skin, pruritus. Skin disorders are highly associated with increased risk of important outcomes, such as 
skin lesions, ulcerations and diabetic foot, which can lead to major complications and revolve around multifactorial 
factors besides hyperglycemia and advanced glycation end products. Although diabetic’s skin disorders are consistent 
in the literature, there is limited data regarding early-stage skin disorders in DM patients. Disease control, early-stage 
treatment (e.g. skin hydration, orthotic devices) and awareness can reduce morbidity of DM patients. Thus, better 
understanding of the burden of skin disorders in DM patients may raise awareness on prevention and management. 
Therefore, the aim of this study is to perform a literature review to evaluate the main clinical characteristics and com-
plications of skin disorders in diabetic’s patients. Additionally, physiopathology early-stage skin disorders and dermo-
cosmetic management were also reviewed.
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Background
Skin disorders, usually neglected and frequently under-
diagnosed among diabetic patients, are common com-
plications and encounter a broad spectrum of disorders 
in both type 1 and type 2 diabetes mellitus (DM)—e.g. 
cutaneous infection, dry skin, pruritus—that can lead 
to major complications and are highly associated with 
hyperglycemia and advanced glycation end products 
(AGEs) [1].
Although diabetic’s skin disorders are consistent in the 
literature, there is limited data regarding early-stage skin 
disorders in DM patients, especially focusing on non-
injured skin [2]. Better understanding of the burden of 
skin disorders in diabetes patients may raise awareness 
on prevention and management. Therefore, the aim of 
this study is to perform a literature review to evaluate the 
main clinical characteristics and complications of skin 
disorders in diabetic’s patients. Additionally, manage-
ment of skin disorders was also reviewed.
Skin disorders in diabetes and epidemiology
Diabetes mellitus (DM) represents a high prevalent dis-
ease with high morbidity and mortality. In 2014, there 
were 387 million diagnosed cases of diabetes and 4.9 mil-
lion deaths worldwide. Additionally, about 77 % of people 
with diabetes live in less developed regions [3]. Although 
prevalence of diabetes morbidity is high, specific data 
on complications related to skin disorders are limited. 
Several epidemiological studies evaluating occurrence 
of skin disorders on type 1 and type 2 DM were per-
formed worldwide, with pattern of skin disorders varying 
according to DM type and region where the study was 
conducted.
Overall prevalence of skin disorder in both type 1 and 2 
DM varied from 51.1 to 97 % in different regions world-
wide. The high prevalence of dermatological disorder 
among DM patients described in literature endorses the 
clinical importance and high impact of this complication.
Although study design and eligibility criteria of the 
included patients varied slightly among reported stud-
ies, most frequent disorder reported in diabetic patients, 
regardless of DM type, was infection—occurring in at 
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infections were more prevalent than bacterial or viral 
infections [4–8], and interdigital spaces, genitalia and 
skin folds were the most frequent site of infection [4].
In a single center epidemiologic study conducted in 
Iran, infection was also the most common lesion reported 
by patients—in this study, the most common noninfec-
tious manifestation was pruritus [9]. Similarly, Sasmaz 
et al. showed that most common skin conditions in DM 
patients are infections (31.7  %), non-candidal intertrigo 
(20.5  %), eczemas (15.2  %), psoriasis (11.2  %), diabetic 
dermopathy (11.2 %), and prurigo (9.9 %) [5].
A study conducted in Brazil evaluated 403 patients 
with type 1 (n = 125) and type 2 (n = 278) DM assisted 
in the outpatient clinic from Ribeirão Preto Hospital 
in 2000. The study demonstrated that 81  % of patients 
had at least one dermatologic lesion, with a mean of 3.7 
lesions per patient, being dermatophytosis the most com-
mon lesion. Of all dermatophytosis, 42.6 % were onycho-
mycoses (n = 172) and 29.2 % were tinea pedis (n = 118). 
Skin lesions occurring in more than 10 % of the patients 
were actinic degeneration (62  %), skin xerosis (20.8  %), 
benign skin tumor (23.5 %), candidiasis (12.9 %) and scar 
(12.6 %) [6].
Another study in Brazil, also conducted in the out-
patient clinic from Ribeirão Preto Hospital from 2003 
to 2004, evaluated 500 DM patients. The study dem-
onstrated that 97  % of all patients had at least one skin 
lesion—the highest skin disorder rate in this review—
being tinea pedis (35  %), candidiasis of the skin/nail 
(26 %), pigmentation disorders (22 %), xerosis (22 %) and 
tinea unguium (22 %) the most commonly reported der-
matological diagnoses among DM patients [10].
A smaller study in Brazil conducted in Canoas with 
55 patients also demonstrated a high prevalence of skin 
disorders among DM patients (89.1  %), comprising of 
yellow nails (52.7  %), candidiasis (52.7  %), dermatophy-
tosis (50.9 %), nail dystrophy (45.5 %) and Staphylococcus 
infections (38.2 %) [11].
Galdeano et al. evaluated 125 patients with type 1 and 
2 DM in a single center in Argentina. The study showed 
a high prevalence of skin disorders: 90.4  %. Skin disor-
ders occurring in more than 10 % of the patients included 
xeroderma (69  %), dermatophytosis (52  %), onychomy-
cosis. (49  %), tineapedis (39  %), peripheral hypotrichia 
(39 %), diabetic dermopathy (35 %) skin thickening syn-
drome (25  %), diabetic foot (24  %), candidiasis (17  %), 
fibroids pendulums (11  %), intertrigo (10  %), and inner 
eyebrow separation (10 %) [12].
In Egypt, Sanad et al. evaluated 100 patients diagnosed 
with type 1 (n = 23) and type 2 (n = 77) DM, with at least 
one skin lesion, in a single center cohort study. The mean 
time of diagnosis was 10.57 ± 7.63 years. In this study, the 
most common skin disorders were cutaneous infections 
(40  %), followed by pruritus (11  %), local reactions at 
the site of insulin injection (8 %), vitiligo (8 %), diabetic 
dermopathy (7  %), periungual telangiectasia (6  %), and 
xanthelasma (5  %). Xerosis was reported in only 3  % of 
patients. Cutaneous infections included fungal (22  %), 
bacterial (16  %), and viral (2  %) infections. Tinea pedis 
was the most common fungal infection (12 %), whereas 
boils were the most common bacterial infection (5  %). 
Among viral infections, one patient had herpes simplex 
and another had herpes zoster [7].
Differences between patterns of lesions remain unclear 
among types of diabetes. A total of five studies evaluated 
skin disorders in both types 1 and 2DM. Chattergee et al. 
showed higher prevalence of skin disorder in type 2 DM 
(75.6 vs 41 %). In this same study, the most common skin 
disorders on type 1 DM were diabetic xerosis, infections 
and diabetic hand. Differently, most frequent disorders pre-
sented in patients with type 2 DM were infections, xerosis, 
hair loss below the knees and diabetic dermopathy [13].
One case–control study evaluating type 1 DM in young 
patients showed that the most prevalent skin disorder 
was xerosis, occurring in 22.2 % of patients compared to 
3  % in the control group (p  <  0.01) [14]. Another study 
evaluating type1 DM in young patients (n =  500), con-
ducted in South Asia, demonstrated that the most com-
mon disorders related to the disease were limited joint 
complication (16.8 %), xerosis (15.8 %) and scleroderma-
like skin changes (10 %). The author also reported com-
plications related to disease treatment, which included 
lipohypertrophy (41 %), postinflammatory hyperpigmen-
tation (3 %) and lipoatrophy (0.6 %) [15].
Additionally, Farshchian et al. also reported differences 
on patterns of infection according to the types of diabe-
tes. In the type 1 DM, the most frequent cutaneous infec-
tions were viral warts, while pyodermas were the most 
frequent cutaneous infections in type 2 DM patients 
[9]. Although prevalence of skin disorders appears to be 
higher in type 2 DM, these disorders should be moni-
tored in early stage regardless of type of diabetes and 
manifestation.
Overall, cutaneous infection and xerosis showed to be 
highly prevalent and important skin disorders in several 
studies, regardless DM type. Among cutaneous infec-
tions, fungal etiology appears to be the most common 
and those with bacterial origin are the less frequent [4–
8]. Other outcomes such as xeroderma, reactions related 
to the treatment, eczema, pruritus, xanthelasma, and 
diabetic dermopathy were also reported and should be 
monitored too.
Although prior studies showed increased risk of infec-
tion in DM patients [16], little evidence is found in the 
literature to support increased risk for cutaneous infec-
tious diseases [9]. In general, skin disorders are highly 
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associated to poorly controlled DM patients. A good 
glycemic control may reduce the incidence and severity 
of cutaneous disorders with or without known patho-
genesis [17]. Nonspecific skin disorders that occur in 
DM patients can increase the likelihood of exposure to 
infectious organisms and contact with allergens, result-
ing in chronic and recurrent infections and eczemas, 
respectively [17]. However, further studies are required, 
since all available data are still not concordant. Addition-
ally, Farshician et al. did not find a significant relationship 
between the diabetic disease control and the prevalence 
of cutaneous infection [9]. Moreover, most cross-sec-
tional studies assessed in this review do not allow causal 
explanations. Thus, further investigation is required to 
better understand the risk of cutaneous infection.
Xerosis was reported in several studies and rates 
showed high heterogeneity. Goyal et  al. showed a high 
prevalence of xerosis (44  %) in a single center observa-
tional study mainly related to weather and dry climatic 
conditions [8]. According to Pavlovic, skin dryness is 
one of the earliest and most common manifestations 
of type 1 DM [14]. Clinical observations are supported 
by a reduced hydration state of the stratum corneum 
and decreased sebaceous gland activity in DM patients, 
without any impairment of the stratum corneum bar-
rier function. Even in the absence of clinically apparent 
xerosis, patients with diabetes have an impaired desqua-
mation process. Furthermore, occurrence of xerosis may 
be affected not only by the type of diabetes but also to 
regional changes in climate and humidity [7].
Major pathways on skin disorders in DM
Skin disorders in DM patients are highly correlated with 
glycemic control. As an example, Foos et al. conducted a 
study with 403 DM patients in Brazil and evaluated their 
skin disorders and glycaemia control. Thus, the study 
demonstrated that 94 % of patients with inadequate gly-
caemia control had some skin disorder; on the other 
hand, only 60 % of DM patients with adequate glycaemia 
control had some skin disorder [6].
DM affects the skin through several mechanisms, being 
hyperglycemia per se and AGEs the most well-described. 
Reaching pathological high levels of glycaemia strongly 
affects skin homeostasis by inhibiting keratinocyte pro-
liferation and migration, protein biosynthesis, inducing 
endothelial cell apoptosis, decreasing nitric oxide syn-
thesis and impairing phagocytosis and chemotaxis from 
several cells [18, 19]. Besides hyperglycemia induce direct 
damage, high glucose levels also induce AGE formation. 
AGEs are formed from glycation of proteins, lipids and 
nucleic acids [18, 19] that act in several pathways, induc-
ing reactive oxygen species (ROS) formation, impairing 
ROS clearance, as well as intra and extracellular proteins 
function, and inducing pro inflammatory cytokine 
through nuclear factor κβ (NF-κβ) pathway [20].
Indeed, AGE biochemical interactions are one of the 
major pathways involved in DM complications, includ-
ing skin disorders [21]. AGE alters collagen properties, 
decreasing flexibility and solubility and increasing its 
rigidity [22]. Also, AGEs participate in the development 
of fibrosis in DM [23], in skin aging [20] and even in dia-
betes-related immunosuppression [24]. Diabetes-related 
immunosuppression affects skin wounding, mainly by 
leukocyte impaired function and misbalanced/malfunc-
tion of growth factors [25].
In addition to the previously mentioned pathways, 
high glucose levels also impair the normal functioning 
of keratinocytes in vitro, decreasing its proliferation and 
differentiation [26, 27]. Moreover, keratinocytes stud-
ies are more commonly conducted in animal models, 
with scarce data on diabetic human skin [2]. Regarding 
epidermal thickness alterations, Bertheim et  al. demon-
strated that diabetic patients with severe joint mobility 
on the hands had an increased epidermal thickness, with 
abnormal hyaluronan distribution on skin layers [28], 
while Zakharov et  al. demonstrated that well-controlled 
patients with type 1 DM did not presented alteration on 
the epidermal thickness [29]. This data reinforces that 
skin disorders in DM patients are strongly related to gly-
caemia control.
Table  1 summary of studies reporting skin disorders 
prevalence in DM 1 and DM 2 patients, with a subjects 
description (number of subjects in the study, type of 
DM evaluated, country/region where the study was con-
ducted, subjects mean age), prevalence of skin condition 
and the most common skin condition in each study.
A summary of skin evaluation studies performed in 
humans is described in Table 2 [28–33].
Cutaneous manifestations in DM patients are mainly 
classified into four categories in order to support man-
agement of the outcomes, especially due to innumerous 
potential causes:
1. Skin lesions with strong to weak association with 
diabetes (necrobiosis lipoidica, diabetic dermopathy, 
diabetic bullae, yellow skin, eruptive xanthomas, per-
forating disorders, acanthosis nigricans, oral leuco-
plakia, lichen planus).
2. Infections (bacterial, fungal).
3. Cutaneous manifestations of diabetic complications 
(microangiopathy, macroangiopathy, neuropathy).
4. Skin reactions to diabetic treatment (sulphonylureas 
or insulin) [4].
Considering cutaneous manifestations on DM, some 
skin conditions are more likely to affect type 1 or 2 DM 
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disproportionally. Although with high inter-study varia-
bility, skin manifestations demonstrating association with 
DM type are described in Table 3 [34].
DM skin disorders progression and potential 
outcomes
An important variability on severity and potential 
outcomes is observed among skin disorders in DM. 
Early-stage skin disorders in DM, such as xerosis, cal-
lus and fissures, are usually neglected and frequently 
underdiagnosed [1]. Lack of diagnosis and treatment on 
early-stage skin disorders can lead to clinical worsen-
ing, and progression to foot neuropathy, ulcers and even 
amputation [35]. DM-induced neuropathy can reach sen-
sory, motor and autonomic pathways, leading to different 
dermatologic conditions (Fig. 1).
  • Sensory neuropathy: insensibility and decreased tem-
perature sensation, affecting the sensibility on lesions 
[36, 37].
Table 1 Summary of studies reporting skin disorders prevalence in DM 1 and DM 2 patients, with a subjects description 
(number of subjects in the study, type of DM evaluated, country/region where the study was conducted, subjects mean 
age), prevalence of skin condition and the most common skin condition in each study
Author Sample size DM type Country/region Age (years) Overall prevalence (%) Overall most frequent 
skin disorder among all 
disorders (%)
Sasmaz et al. [5] 151 Type 2 India 54 ± 17 85.4 Cutaneous infection 
(20.6 %)
Chatterjee, et al. [13] 680 Types 1 and 2 India 46.3 ± 6.7 73.9 Cutaneous infection 
(40.9 %)
Farshchian et al. [9] 155 Types 1 and 2 Iran 21.8 ± 4.9 and 
57.2 ± 9.7, type 1  
and 2, respectively
71 Cutaneous infection
Foss et al. [6] 403 Types 1 and 2 Brazil 19.9 ± 2.3 and 
63.1 ± 3.4 type 1  
and 2, respectively
81 Cutaneous infection 
(82.6 %)
Wambier et al. [10] 500 Types 1 and 2 Brazil 45.5 ± 20 97 Cutaneous infection 
(i.e.Tinea pedis) (35 %)
da Silva et al. [11] 55 Type 2 Brazil 56.3 ± 13.4 89.1 Yellow nails (52.7 %) and 
candidiasis (52.7 %)
Galdeano et al. [12] 125 Types 1 and 2 Argentina 58.9 ± 15.43 90.4 Xeroderma (69 %)
Pavlovic et al. [14] 212 Type 1 Servia 12.5 ± 3.7 68 Xerosis (22.2 %)
Romano et al. [4] 457 Types 1 and 2 Italy 61.5 ± 11.3 60 Cutaneous infection
Sanad et al. [7] 100 Types 1 and 2 Egypt 51.42 ± 14.66 – Cutaneous infection 
(40 %)
Sawatkar et a [15]l 500 Type 1 South Asia 16.9 ± 6.9 67.8 Limited joint mobility 
(16.8 %)
Goyal et al. [8] 100 Types 1 and 2 India 57.44 ± 10.37 – Xerosis (44 %)
Ragunatha et al. [17] 500 Types 1 and 2 India 55.24 ± 11.24 51.1 Cutaneous infection
Table 2 Summary of findings on skin alterations in DM patients
Adapted from Quondamatteo [2]
Parameter Effect in DM patients Reference
Hydration Decreased Sakai et al. [30]
No alteration Seirafi et al. [31]
Trans-epidermal loss Not altered Sakai et al. [30]
Seirafi et al. [31]
Filaggrin Alteration Thyssen et al. [32]
Other possible signs of barrier defect Increased inflammatory infiltration Tellechea et al. [33]
Epidermal thickness No alteration Zakharov et al. [29]
Thicker epidermis Bertheim et al. [28]
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  • Motor neuropathy: causes toe and gait deformity, 
leading to foot deformity and increased plantar pres-
sure [38, 39].
  • Autonomic neuropathy: leads to anhidrosis and vaso-
dilation, causing dry skin, skin tears and fissures [40], 
also losing viscoelasticity [41].
All the neuropathies, alone or simultaneously, can lead 
to neuropathic foot ulcer, the most severe cutaneous 
lesion, in consequence of the poor healing potential of 
DM skin [42] that frequently become infected, thus lead-
ing to amputation [43, 44].
Complications prevention by treating chronic hyper-
glycemia and early-stage symptoms (e.g. skin hydration, 
orthotic devices, patient education) is highly acclaimed 
by medical society, once the diabetic foot brings severe 
economic, personal, social, and medical impact [35, 45]. 
Furthermore, xerosis, callus and foot deformity are the 
early-stage complications target to avoid the develop-
ment of diabetic foot. Besides, a continuous patient edu-
cation is also required to ensure that patients take proper 
care of the skin and foot.
Although several clinical outcomes related to DM, 
many cellular impairments are also related to hyperglyce-
mia and hyperinsulinemia. As an example, keratinocytes, 
which is the predominant cell type in the epidermis, 
are downregulated in hyperglycemia conditions, with 
impairment on its proliferation [26]. In addition, a study 
performed in animal model demonstrated an imbalance 
on stratum corneum composition (lower triglycerides 
and higher ceramides, cholesterol and fatty acids levels), 
when compared to control. Furthermore, another study 
showed an increased number of corneocyte layers in the 
stratum corneum and decreased basal cell proliferation 
and epidermal DNA content—important in epidermal 
differentiation—suggesting slower stratum corneum and 
epidermal turnover [46]. Moreover, larger corneocyte 
surface area is observed in DM patients, when compared 
to control [47].
The dermis also suffers morphological and biochemi-
cal alteration in DM patients due to the synthesis and/
Table 3 Most frequent skin disorders among  type 1 
and type 2 DM
Adapted from Murphy-Chutorian et al. [32]
Type 1 diabetes mellitus Type 2 diabetes mellitus
Necrobiosis lipoidica diabeticorum Generalized granuloma annulare
Diabetic bullae Scleredema diabeticorum
Vitiligo vulgaris Diabetic dermopathy
Periungual telangiaecstasia Acathosis nigricans
– Acrochordons
– Psoriasis
Fig. 1 Neuropathic foot ulcer pathophysiology. Neuropathic foot ulcer physiopathology pathways, with autonomic, motor and sensory neuropa-
thies leading to foot neuropathy. Adapted from Boulton [37]
Page 6 of 8de Macedo et al. Diabetol Metab Syndr  (2016) 8:63 
or degradation of intracellular matrix and microarchitec-
tural arrangement. Moczar et al. [48] demonstrated that 
skin biopsies of DM patients had ultrastructural modi-
fications on fibroblast, collagen and elastic fibers in the 
dermis, with fragmented or absent elastic fibers under 
the epithelial basal laminae. Additionally, DM patients’ 
dermis presented collagenase and elastase alterations, 
endorsing the important matrix macromolecules altera-
tions on DM patient’s dermis
As a result of all those changes, lower plasticity of the 
epidermis is seen in DM patients when compared to 
controls [49], without any alteration in transepidermal 
water loss (TEWL) [30, 31]. Furthermore, skin surface 
lipids appeared to be reduced in DM patients [30, 31]; 
also, another study demonstrated decreased skin elas-
ticity in the forearm and forehead. Some of the func-
tional properties of the stratum corneum in DM patients 
vary according to acute uncontrolled glycaemia (fast-
ing plasma glucose  >  110  mg/dL) and disease control 
(HbA1c > 5.8 %). In DM patients with fasting plasma glu-
cose higher than 110 mg/dL, skin surface hydration was 
lower than in DM patients with fasting plasma glucose 
lower than 110 mg/dL, with no alteration on TEWL. On 
the other hand, patients with HbA1c levels higher than 
5.8  % have slightly lower TEWL on forearm, with no 
alteration on skin surface hydration, when compared to 
patients with HbA1c < 5.8 % [30].
In conclusion, dermocosmetic strategy is an option to 
treat the biophysical alterations on DM skin, with efficacy 
on improving skin hydration, decreasing xerosis and scal-
ing among other factors [50].
Skin hydration: avoiding the progression
Dermocosmetic management through skin hydration 
and control of xerosis and callus symptoms are essen-
tial to avoid progression of skin lesions on DM patients 
[51]. Regarding dermocosmetic approach, the most com-
monly used active ingredient is urea. In 2003, Schöler-
mann et al. published the results of two studies with 10 % 
urea cream in dry skin treatment. In the first study, 603 
patients with dry or extremely dry skin, of which 179 
were DM patients, were treated with 10  % urea cream 
for 14 days, presenting a decrease on dryness, callosities 
and scaling compared to baseline. In the second study, 30 
patients with diabetes and/or xerosis were treated in one 
foot (the other foot was used as control) with 10 % urea 
cream for 10 days, resulting in decreased callosities, dry-
ness and scaling [52].
Federici et  al. conducted a randomized controlled 
clinical trial with 40 type 2 DM patients who were allo-
cated to receive urea 5 %, arginine and carnosine versus 
a glycerol-based emollient for 28  days. Patients treated 
with urea 5 %, arginine and carnosine presented an 89 % 
reduction on dryness according to DASI scale when com-
pared to control emollient [53]. Another study conducted 
with 54 type 1 and 2 DM patients treated with 10 % glyc-
erin, 5 % urea, 1 % lactic acid (moisturizing agents) and 
8 % paraffin (occlusive agent) in an emulsion base versus 
placebo (emulsion base with none of the active ingredi-
ents) for 4 weeks also demonstrated a decrease of dryness 
and fissures and increased skin hydration on active-
treated group [54].
Similar studies were performed with 10 % urea and 4 % 
lactic acid [55]; 10 % urea, Oenothera biennis oil, Centella 
asiatica extract, α-hydroxy acid, allantoin, and panthe-
nol formulation [56]; 5  % urea with 0.2  % hydroxyeth-
ylpiperazine ethane sulfonic acid [57]. Polaskova et  al. 
performed a study comparing the 6 urea-containing dif-
ferent formulations for diabetic foot, evaluating TEWL, 
and demonstrated that urea 6 % formulations maintained 
or restored adequate barrier function, while urea 4 % for-
mulations presented longer action period [58].
Recently, Nunes et  al. published a study performed in 
87 Brazilian DM patients evaluating efficacy and safety of 
cream (n = 43) or lotion (n = 44) Hidrastar formulations, 
containing urea, amino acids, linoleic acid, linolenic acid 
and SH-oligopeptide-2. After 28 days of application twice 
a day in both feet, 100  % of the patients using Hidrastar 
cream formulation reported increase in skin hydration, 
softness, improved texture and overall appearance. In the 
group using Hidrastar lotion formulation, 79.5 % of patients 
reported increased hydration, 81.8 % increase in softness, 
81.8 % improvement in texture and 86.4 % improvement in 
the overall appearance of the skin of the feet [59].
Conclusion
In conclusion, our review confirmed high prevalence of 
skin disorder in DM patients, showing that careful der-
matological examination and outpatient follow-up of 
DM patients is required to provide them adequate skin 
management, thus reducing morbidity and complications 
related to skin. Additionally, in early-stage disorders, 
such as xerosis and callus, detection and management 
appeared to be important in reducing complications 
related to DM. This review summarizes the main articles 
in skin disorders and diabetes, with some limitations as 
the absence of statistical summary, from a meta-analy-
sis. Further observational studies are required to clarify 
differences between types of diabetes and association 
between disease and risk of occurrence.
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